Cadence says it now treats more than 100,000 chronic-disease patients, and it has just raised $100 million to treat many more. The Series C round was led by Spark Capital, with Thrive Capital, General Catalyst, Coatue and others joining in, among them Corewell Health Ventures. So did two health systems, Memorial Hermann and Duke Health.
That last pair matters. Hospitals do not usually put money into software they regard as a nice extra.
What the company does
Cadence calls itself a clinical AI company that manages the long-term illnesses of older adults. Its supervised AI agents sit inside a partner health system’s medical group, electronic records and clinical workflows. They watch patients’ vitals every day, support timely medication changes and give personalised lifestyle coaching. Doctors stay in charge of care plans and treatment decisions.
The target is a big one: the company points to over 56 million older adults living with chronic disease, at a time of clinician shortage. Such illness is the biggest single source of healthcare spending in America, it says, and much of that spending could be avoided.
“We built Cadence to solve the clinical labor constraint at the heart of the chronic disease crisis,” said Chris Altchek, founder and CEO. “We’re treating 100,000 patients with that system today, alongside partners committed to changing the status quo in chronic care. This investment builds the infrastructure to treat millions.”
The numbers it offers
Alongside the funding, Cadence said it had added Duke Health and Texas Health Resources as affiliates, so it now works with over 20 health systems. It also made a series of claims about results:
Alerts about incoming vitals get a median response time of 3.5 minutes, and 55% are resolved appropriately without a human having to step in. The company estimates that its model cuts hospital admissions by 27% and saves roughly $1,302 per patient each year. Medicare, it says, gets back more than three dollars for each dollar spent delivering the care, and the weekly saving to the programme is roughly $2.7 million. Annual recurring revenue tripled in 2025. Peer-reviewed studies, it adds, show patients with heart failure sticking to treatment better and people with hypertension controlling their blood pressure more effectively. These are the company’s own figures.
Why investors and hospitals are interested
Will Reed, a partner at Spark Capital who joins the Cadence board, said the company has “done the hardest work first”: showing clinical outcomes, earning the trust of leading health systems and proving that AI can be deployed safely inside care delivery.
Jeffrey Ferranti, Duke Health’s chief digital officer, framed it from the patient’s side. “The moments that matter most for a patient’s health often happen at home, not in the clinic,” he said. With Cadence, he said, Duke keeps in contact with chronically ill patients day and night and can step in early.
The money will go to AI development, adding health systems and value-based care, in which providers are paid for keeping patients healthy. Patients with any of these conditions should discuss home monitoring with their own doctor.
Sources
- Cadence Raises $100M Series C Led by Spark Capital to Automate Chronic Care
- Cadence Raises $100M to Expand AI Chronic Care Platform
